Among all the inaccurate things that are stated about

New Post Public Reply Private Reply Replies (0) Message Board
bejamin
Among all the inaccurate things that are stated about Cellceutix the top 2 seem to be time line and credibility. Both can be squashed with good DD. As the company moves forward, especially in such a position of success, there will be many that try to mince every word that is written and or said.

Facts -
The company never gave any time line to up-list except one time in an interview saying the plan was for this year (2015) The rumblings that this has lead investors wrong is very inaccurate! As good as Cellceutix has been at keeping investors updated(I for one have appreciated), has also keep the wolves close by the door. Giving them the opportunity to smash down every bit of news that is released and turn it in to a non event, as seen in the false SA article. So they will keep carrying that torch and may proclaim that partner or up-list is the only way to save the company.The company doesn't require a high SP to conduct and continue through trials this has been discussed ad nausseam! They only thing the attacks on the company have done was drop SP it hasn't slowed anything else down! Well maybe partner discussions, but I don't even think that matters as Cellceutix stands in a position to negotiate anyway.

I would also like to state that Cellceutix has been working very hard to do the up-list so they are reporting and filing at the level required to be on NASDAQ, they aren't trying to con anybody.

When your doing your DD find it in print. You will be told things like Phase 2 is meaningless phase 3 is the answer, the same thing was said about phase 1 to phase 2. Phase 3 is a given now and just waiting for the "real" time it takes to set up a trial. But if you look at the phase 2 results you will see phase 3 has been very de-risked by the quality of the results. Kevetrin is the same thing phase one took longer than expected(welcome the world of medicine development). But the quality of the results are outstanding, by a hospital that is equally outstanding!
Cellceutix isn't a guaranteed success by no means. But if you take a look at where it is, I would much rather be putting my money in a bio with 5 trials, 3 major drugs and phase 2s going on and completed and a phase 3 about to start, over a bio with one drug. Do the math look around compare values of companies.
When you get to money "issue" they have a lot of funding on hand, should they need it. Take a good look at how much the company is burning through! They are using a lot of grants and some trials they are just supplying the drugs.

Remember it is the internet where names have been change to protect... everybody... so consider the source of the information you receive. Then make a real assessment of the company if you are really considering investing in the company on the long side!


Know What you own

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Keep in mind that message boards require you to agree to thier manipulation or you are a lying basher! Also remember those that accuse are often riddle with quilt of performing the same which they accuse.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Rock Gate Buys Aviation Niche Player Blast Deflectors

Updated Category News Views 52

Jet exhaust is not glamorous, but somebody has to keep it from battering everything nearby. Rock Gate Partners’ acquisition of Blast Deflectors, Inc. puts money behind one of those stubbornly unsexy industrial niches where engineering credibility matters far more than a flashy sales pitch. The transaction closed October 16, 2026, and Northborne Partners announced...

Continue Reading
CCTV-4 Revisits China's Enduring Academy Tradition

Updated Category News Views 76

Stone courtyards, old books and hard questions are getting prime time on CCTV-4, which is a more interesting programming bet than it may first appear. Enduring Chinese Academies, a ten-episode cultural exploration series from China Media Group's Global Chinese Programming Center, is built around a simple theme: “One academy, one spirit.” It begins airing November 22...

Continue Reading
Tigo's Guidance Gap Draws Lawsuit and Investor Scrutiny

Updated Category News Views 69

A Revenue Promise Hit the Wall Solar investing can turn ugly in a hurry when a supposedly near-term catalyst gets shoved down the calendar. That is the central bruise behind the securities class action involving Tigo Energy, not some arcane accounting footnote that only lawyers can love. The complaint alleges Tigo overstated the revenue contribution it expected from its...

Continue Reading
Sleep Number’s Couples Pitch Has Some Fine Print Too

Updated Category News Views 75

A thermostat war in the bedroom is a lousy reason to buy the wrong mattress. Yet that is the mundane, very real problem Sleep Number is leaning into after Expert Consumers named it a leading 2026 choice for couples seeking personalized sleep comfort. The company’s argument is straightforward: two people sharing a bed should not have to share one firmness setting, or...

Continue Reading
Trip.Best Expands Global Travel Discovery Footprint

Updated Category News Views 123

Sydney just became the map pin for a fairly serious travel-content land grab. Trip.Best, Trip.com Group's ranking brand, has rolled out its 2027 Annual Rankings with coverage of all seven continents for the first time. This is not an earnings release, and nobody should pretend a hotel list magically turns into revenue by lunchtime. Still, the jump from 85 to 98 annual...

Continue Reading
Duetti, CesiumAstro, and a Busy NYSE Capital Morning

Updated Category News Views 73

Three very different piles of money are jamming up the November 20 NYSE slate, and that contrast is the whole point. Private music catalogs, space-and-defense communications, and a new stock-and-bond ETF do not belong in the same bucket. Yet all three are competing for investor attention before the opening bell, alongside Danaos Corporation's 20th listing anniversary....

Continue Reading
PayPal Adds a Risk Hand to Its Board at a Crucial Turn

Updated Category News Views 48

A Boardroom Hire With Some Actual Weight PayPal did not go hunting for another decorative résumé. Brian J. Lee, set to join the board on November 30, 2026, spent decades inside Goldman Sachs, including a stint as chief risk officer from 2019 through January 2025. For a payments company trying to sharpen its financial-services identity, that is a serious piece of...

Continue Reading
AlphaPoint's Approval Device Targets AI Attack Risk

Updated Category News Views 45

A Separate Screen May Be Worth More Than Another Patch AlphaPoint is taking a fairly old security instinct and aiming it at a very current headache: if the laptop is lying to the employee, do not let the laptop have the final say. Its newly introduced Approval Device is dedicated hardware with its own display, built to let authorized staff inspect and approve sensitive...

Continue Reading
Milwaukee County Contract Tests Wisconsin Labor Shift

Updated Category News Views 6

A unanimous first contract in a Milwaukee County department is not the sort of headline that rattles a trading screen, but it can tell you plenty about where the ground is moving. Public safety workers in the county Facilities Department have ratified their first agreement with Teamsters Local 344, according to the union. The vote matters less for any disclosed economic...

Continue Reading
Pennsylvania Housing Finds Its October Holding Pattern

Updated Category News Views 79

Pennsylvania's October housing numbers have the uneasy stillness of a pond before somebody throws a rock. The statewide median sales price sat at $315,000, exactly where it was in September, while sales barely cleared 10,400 and available listings kept inching higher. Nothing in that mix screams boom or bust. Frankly, that is the point: a market can look calm on the...

Continue Reading

Top 5 Most Recently Viewed Articles

Indovinya Unveils Challenge for Innovative Fragrance Solutions

Updated Category News Views 148

Indovinya Launches Open Innovation Challenge Researchers and startups with a focus on developing sustainable solutions for fragrance solubilization are invited to apply for an exciting new challenge initiated by Indovinya, the specialty chemicals and surfactants division of Indorama Ventures. The aim is to enhance fragrance solubilization without the use of ethoxylates,...

Continue Reading
Capricor Therapeutics to Highlight Innovations at Investor Events

Updated Category News Views 156

Capricor Therapeutics to Highlight Innovations at Investor Events Capricor Therapeutics (NASDAQ: CAPR), a leading biotechnology company based in San Diego, is committed to developing transformative cell and exosome-based therapies aimed at addressing rare diseases. Recently, the company announced a series of presentations scheduled at prominent investor conferences, where...

Continue Reading
Trump Media Takes Bold Step Into Financial Sector with New ETFs

Updated Category News Views 179

Trump Media's Financial Leap Trump Media & Technology Group Corp. (NASDAQ: DJT) is embarking on an exciting journey into the financial landscape. The company's fintech and streaming divisions are rolling out an innovative suite of five new exchange-traded funds (ETFs). These funds are crafted around the compelling themes of 'America First', aiming to appeal to socially...

Continue Reading
Vascular Access Device Market Set to Hit $8.68 Billion Milestone

Updated Category News Views 133

Overview of the Vascular Access Device Market The vascular access device market is on a promising trajectory, projected to escalate from around USD 6.27 billion to USD 8.68 billion by 2031, reflecting a compound annual growth rate (CAGR) of 6.7%. This significant growth is positioned to enhance patient care in various healthcare settings, emphasizing the vital role of...

Continue Reading
Oscar Health: Navigating the Storm in Health Insurance Market

Updated Category News Views 269

Oscar Health: Understanding the Current Landscape The US health insurance sector is facing unprecedented challenges this year. With a significant number of individuals at risk of losing health insurance coverage due to substantial budget cuts, many are seeking medical care while they still can. This surge in demand has resulted in soaring utilization rates, pushing...

Continue Reading